[{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Universal Cells","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ginkgo Bioworks \/ Universal Cells","highestDevelopmentStatusID":"3","companyTruncated":"Ginkgo Bioworks \/ Universal Cells"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ginkgo Bioworks \/ Biogen","highestDevelopmentStatusID":"1","companyTruncated":"Ginkgo Bioworks \/ Biogen"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ginkgo Bioworks \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"TAK-919","moa":"SARS-CoV-2-viral spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ginkgo Bioworks \/ Moderna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Ginkgo Bioworks \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Ginkgo Bioworks \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ginkgo Bioworks \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Novo Nordisk"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ginkgo Bioworks \/ Pfizer Inc","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Pfizer Inc"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ginkgo Bioworks \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Novo Nordisk"}]

Find Clinical Drug Pipeline Developments & Deals by Ginkgo Bioworks

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details : This collaboration underscores Ginkgo's capacity to deploy high-throughput biological approaches to tackle the complex challenge set associated with development of therapies targeting solid tumors.

Product Name : Undisclosed

Product Type : Cell and Gene therapy

Upfront Cash : Undisclosed

January 13, 2025

Lead Product(s) : Undisclosed

Therapeutic Area : Oncology

Highest Development Status : Discovery Platform

Sponsor : Universal Cells

Deal Size : Undisclosed

Deal Type : Collaboration

blank

02

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details : The partnership aims to enhance the manufacturing of Novo's medicines for serious chronic diseases, including diabetes and obesity, leveraging Ginkgo's synthetic biology platform for new methods.

Product Name : Undisclosed

Product Type : Undisclosed

Upfront Cash : Undisclosed

October 04, 2024

Lead Product(s) : Undisclosed

Therapeutic Area : Endocrinology

Highest Development Status : Discovery

Sponsor : Novo Nordisk

Deal Size : Undisclosed

Deal Type : Expanded Collaboration

blank

03

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details : The financing will be used to develop a novel live cell therapeutic that can produce antibodies to fight human immunodeficiency virus (HIV) and/or malaria directly in the body.

Product Name : Undisclosed

Product Type : Undisclosed

Upfront Cash : Undisclosed

December 13, 2023

Lead Product(s) : Undisclosed

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Discovery

Sponsor : Bill & Melinda Gates Foundation

Deal Size : Undisclosed

Deal Type : Funding

blank

04

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details : Under the collaboration, Pfizer will leverage Ginkgo's proprietary RNA technology to advance the discovery and development of novel RNA molecules across priority research areas.

Product Name : Undisclosed

Product Type : Undisclosed

Upfront Cash : Undisclosed

September 27, 2023

Lead Product(s) : Undisclosed

Therapeutic Area : Technology

Highest Development Status : Discovery

Sponsor : Pfizer Inc

Deal Size : $331.0 million

Deal Type : Collaboration

blank

05

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details : The companies will leverage Ginkgo's natural product discovery capabilities to accelerate the discovery and development of novel therapeutic molecules to address diseases with high unmet patient needs that are out of reach of conventional drug discovery.

Product Name : Undisclosed

Product Type : Undisclosed

Upfront Cash : Undisclosed

August 05, 2023

Lead Product(s) : Undisclosed

Therapeutic Area : Technology

Highest Development Status : Discovery

Sponsor : Boehringer Ingelheim GmbH

Deal Size : $406.0 million

Deal Type : Partnership

blank

06

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details : Using synthetic biology, Ginkgo and Novo Nordisk will collaborate to unlock the potential of expression systems, which may accelerate and enhance the discovery and development of Novo Nordisk's biological medicines.

Product Name : Undisclosed

Product Type : Undisclosed

Upfront Cash : Undisclosed

July 06, 2022

Lead Product(s) : Undisclosed

Therapeutic Area : Endocrinology

Highest Development Status : Discovery

Sponsor : Novo Nordisk

Deal Size : Undisclosed

Deal Type : Collaboration

blank

07

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details : Biogen will receive access to Ginkgo’s proprietary cell programming platform and capabilities. Ginkgo will utilize its bioengineering facilities and resources with the aim of enhancing the AAV production titers of Biogen’s gene therapy manufacturing ...

Product Name : Undisclosed

Product Type : Undisclosed

Upfront Cash : $5.0 million

May 21, 2021

Lead Product(s) : Undisclosed

Therapeutic Area : Neurology

Highest Development Status : Undisclosed

Sponsor : Biogen

Deal Size : $120.0 million

Deal Type : Collaboration

blank

08

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details : The deal is focused on exploring potential optimizations to Moderna's processes for generating some of the key raw materials used in the manufacturing of its mRNA vaccines, including for mRNA-1273.

Product Name : mRNA-1273

Product Type : Vaccine

Upfront Cash : Undisclosed

April 15, 2020

Lead Product(s) : TAK-919

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase I

Sponsor : Moderna Therapeutics

Deal Size : Undisclosed

Deal Type : Collaboration

blank